Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

CVS, Walmart, Walgreens Agree On $13.8B Opioid Related Lawsuit Settlement

Published 02/11/2022, 11:53
Updated 02/11/2022, 13:10
© Reuters.  CVS, Walmart, Walgreens Agree On $13.8B Opioid Related Lawsuit Settlement

  • CVS Health Corp (NYSE: NYSE:CVS), Walgreens Boots Alliance (NASDAQ:WBA) Inc (NASDAQ: WBA), and Walmart Inc (NYSE: NYSE:WMT) have reportedly agreed to pay about $13.8 billion to resolve several lawsuits accusing the companies of the opioid epidemic in the U.S.
  • The proposed settlement calls for CVS to pay $5 billion over ten years, Walgreens to pay $5.7 billion over 15 years, and Walmart to pay $3.1 billion, mostly upfront.
  • CVS Health issued a news release regarding the settlement of $5 billion over ten years starting in 2023.
  • The company will pay $4.9 billion to states & political subdivisions and approximately $130 million to tribes.
  • The proposed settlement, which would be the first nationwide deal with retail pharmacy companies, Reuters reported, follows nationwide opioid settlements with drugmakers and distributors totaling more than $33 billion.
  • State and local authorities have said they will use the settlement money to combat the opioid crisis, which according to federal government data, has caused nearly 650,000 overdose deaths since 1999.
  • Photo by Thomas Breher from Pixabay
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.